Shares of Tandem Diabetes Care Inc. (NASDAQ:TNDM) traded down 0.9% during trading on Monday . The company traded as low as $6.94 and last traded at $6.99, with a volume of 55,878 shares traded. The stock had previously closed at $7.05.

A number of analysts have recently commented on the stock. Zacks Investment Research raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $8.25 price objective on the stock in a research report on Wednesday, July 6th. Wedbush reissued an “outperform” rating and issued a $20.00 price objective on shares of Tandem Diabetes Care in a research report on Friday, July 29th. Sterne Agee CRT reissued a “neutral” rating on shares of Tandem Diabetes Care in a research report on Monday, May 16th. Finally, Robert W. Baird reissued a “buy” rating on shares of Tandem Diabetes Care in a research report on Monday, May 2nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. Tandem Diabetes Care presently has an average rating of “Hold” and a consensus price target of $14.21.

The stock’s market cap is $214.60 million. The stock has a 50 day moving average of $7.13 and a 200-day moving average of $7.97.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, July 28th. The medical device company reported ($0.60) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.05. During the same quarter in the prior year, the firm posted ($0.65) earnings per share. The firm earned $23 million during the quarter, compared to the consensus estimate of $23.08 million. The company’s revenue was up 46.5% on a year-over-year basis. On average, equities research analysts anticipate that Tandem Diabetes Care Inc. will post ($2.14) EPS for the current fiscal year.

In related news, EVP John F. Sheridan sold 15,000 shares of the business’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $6.52, for a total value of $97,800.00. Following the sale, the executive vice president now directly owns 22,763 shares in the company, valued at approximately $148,414.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.